XPH - SPDR S&P Pharmaceuticals ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
-0.24 (-0.64%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close37.30
Bid37.10 x 1000
Ask37.12 x 1200
Day's Range37.04 - 37.53
52 Week Range34.51 - 48.98
Avg. Volume69,881
Net Assets186.17M
PE Ratio (TTM)N/A
YTD Return3.47%
Beta (3Y Monthly)1.34
Expense Ratio (net)0.35%
Inception Date2006-06-19
Trade prices are not sourced from all markets
  • Stock market news: August 27, 2019
    Yahoo Finance

    Stock market news: August 27, 2019

    U.S. stocks swung into negative territory, ending Tuesday’s session lower after a closely watched portion of the Treasury yield curve inverted further and stoked fears of a recession.

  • ETF Trends

    8 ETFs to Capture Opportunities in Healthcare Sector

    Institutional investors and hedge funds have shifted away from technology names as the U.S.-China trade war extends and picked up battered healthcare names. Retail investors can also gain exposure to the ...

  • Pharma Q2 Earnings Growth Highest: Time to Buy ETFs?

    Pharma Q2 Earnings Growth Highest: Time to Buy ETFs?

    Despite robust results, pharma ETFs have been trending downward in a month.

  • ETF Trends

    4 Hot Pharmaceutical ETFs

    Pharmaceutical ETFs invest in stocks of companies that are involved in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. With Johnson and Johnson continuing ...

  • Why disclosing drug prices in TV ads won't lower costs
    Yahoo Finance

    Why disclosing drug prices in TV ads won't lower costs

    The Trump administration said if drugmakers disclose prices in TV ads costs will go down. But that may not necessarily be the case.

  • MarketWatch

    Health stocks under pressure in wake of Trump plan to issue executive order on drug pricing

    Shares of health companies were down Monday, with both the Health Care Select Sector SPDR Fund ETF and the SPDR S&P Pharmaceuticals ETF falling 0.6% in morning intraday trade. Shares of Cardinal Health Inc. led the losers in the S&P 500's health-care ETF, falling 3.1% after the company said CFO Jorge Gomez would leaving the company, followed by declines in shares of Incyte Corp , Alexion Pharmaceuticals Inc. , and Biogen Inc. , Regeneron Pharmaceuticals Inc. and Amgen Inc. . The dip in health-care stocks comes after President Trump's announcement Friday that he was planning to soon issue an executive order allowing the U.S. to buy drugs based on the lowest price paid by other developed countries. "Our guess is drug stocks may be initially pressured this week," Jefferies health-care trading desk strategist Jared Holz wrote in an email to clients on Sunday evening. However, "feedback already suggests investors believe the executive order, if it comes to pass, will only be relevant for a handful of drugs (those that are very significant in revenue and administered in a physician's office)... at least at the onset," he wrote. The drop in health shares comes amid a broader decline in U.S. stocks, as investors grapple with doubts about whether the Federal Reserve will still cut interest rates after a strong U.S. jobs report Friday. The S&P 500 was down 0.4% Monday morning. The index has gained 18.8% in the year to date.

  • Trump Today: President leans on Fed anew and mulls census executive order

    Trump Today: President leans on Fed anew and mulls census executive order

    President Donald Trump on Friday applied fresh pressure on the Federal Reserve over interest-rate policy, and told reporters he was considering an executive order over a citizenship question on the 2020 census.

  • AbbVie to Buy Allergan: Prescribed ETFs

    AbbVie to Buy Allergan: Prescribed ETFs

    AbbVie has agreed to buy Botox-maker Allergan for $63 billion in a cash-and-stock deal. The news has put the spotlight on a number of healthcare ETFs.

  • ETF Trends

    AbbVie, Allergan Deal Puts Spotlight on Pharmaceutical ETFs

    Pharmaceutical sector-specific exchange traded funds showed mixed results Tuesday after AbbVie (NYSE: ABBV) agreed to acquire Allergan (NYSE: AGN) for $63 billion. Among the largest pharma-specific ETFs, ...

  • MarketWatch

    Drug maker stocks rally after AbbVie's deal to buy Allergan for 45% premium

    Shares of drug makers were getting a nice boost in premarket trading Tuesday, after AbbVie Inc.'s deal to buy Allergan PLC for a 45% premium. The SPDR S&P Pharmaceuticals ETF rallied 2.2% ahead of the open. Besides the 31% jump in Allergan's stock, among other shares seeing nice gains in the premarket, Mylan N.V. rose 2.7%, Endo International PLC climbed 4.5%, Theravance Biopharma Inc. hiked up 4.2%, Mallinckrodt PLC tacked on 2.7% and Perrigo Co. PLC gained 2.2%. Meanwhile, Medicines Co.'s stock shed 4.6%, after the company announced late Monday the public offering of $150 million worth of common stock. The pharmaceuticals ETF has lost 7.7% over the past three months through Monday, while the S&P 500 has gained 5.3%.

  • ETF Trends

    Legal Troubles Beset Pharmaceutical Sector ETFs

    Pharmaceutical ETFs may be in trouble with legal troubles looming over the industry. The drugmaker segment recently sold-off after an amended civil antitrust complaint brought by more than 40 state attorneys ...

  • Pharma ETFs Down Despite Solid Q1 Results

    Pharma ETFs Down Despite Solid Q1 Results

    Despite such robust results, pharma ETFs have been trending downward in a month.

  • 3 Healthcare ETFs to Sell Amid Political Headwinds

    3 Healthcare ETFs to Sell Amid Political Headwinds

    The healthcare sector, the second-largest sector by exposure in the S&P 500, is in the midst of a dismal run. After ranking as the best-performing sector in the U.S. last year, healthcare is the worst-performing group in the S&P 500 in 2019.Just look at the Health Care Select Sector SPDR (NYSEARCA:XLV), the largest of healthcare ETFs by assets. XLV is down 0.84% year-to-date while the S&P 500 is higher by nearly 16%. XLV's year-to-date loss does not paint a complete picture of healthcare stocks' weakness. Investors' distaste for the sector has recently been increasing as highlighted by an April loss of more than 7% for XLV.While the long-term outlook for the healthcare sector remains solid, healthcare ETFs and stocks face myriad headwinds, including some that are politically-charged. As has been widely noted, the idea of Medicare For All has significant traction among several Democrats running for that party's 2020 presidential nomination and that is plaguing insurance providers and some more focused healthcare ETFs.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMore recently, politicians from both parties continued assailing high pharmaceuticals prices, sending the S&P Pharmaceuticals Select Industry Index lower by more than 6% for the week ending April 18. * 10 High-Yielding Dividend Stocks That Won't Wilt In other words, healthcare ETFs face a lot of near-term headwinds, meaning it could be time to consider dumping these funds. SPDR S&P Pharmaceuticals ETF (XPH)Source: Shutterstock Expense ratio: 0.35% per year, or $35 on a $10,000 investment.The SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) tracks the aforementioned S&P Pharmaceuticals Select Industry Index and even with the recent consternation over high drug prices, this healthcare ETF is maintaining a year-to-date gain of over 6%. That makes XPH one of the better-performing healthcare ETFs this year.The White House claims that it has affected favorable changes when it comes to drug prices, but with a presidential election year looming, the rhetoric on this issue is likely to increase, not abate, and that presents a potential headwind for a slew of healthcare ETFs, including XPH."Even if politicians truly wanted to lower drug prices, one complexity is that Medicare, which many candidates want to expand broadly, has no authority to negotiate thanks to a possibly ill-advised policy proposed by the Bush administration that has been in effect since 2006," according to CNBC.XPH and several other healthcare ETFs are front-and-center in the drug price debate. XPH's deteriorating technical health is another cause for concern with this healthcare ETF as the fund currently resides more than 10% below its 200-day moving average, a percentage that has recently been growing. Invesco S&P SmallCap Health Care ETF (PSCH)Source: Shutterstock Expense ratio: 0.29%The combination of small-cap stocks and the healthcare sector can be rewarding for investors when both of those elements are moving higher in unison. Small caps are doing their jobs this year, but healthcare is not, and that drag has recently been weighing on the Invesco S&P SmallCap Health Care ETF(NASDAQ:PSCH).PSCH, the small-cap counterpart to the aforementioned XLV, is a diversified healthcare ETF and its 69 holdings "are healthcare companies principally engaged in the business of providing healthcare-related products, facilities and services, including biotechnology, pharmaceuticals, medical technology and supplies," according to Invesco. * 7 Digital Ad Stocks That Deserve Your Attention Right Now In more sanguine environments for the healthcare sector, PSCH's diverse roster would be an advantage. For the time being, the opposite is true. PSCH's nearly 13% weight to pharmaceuticals stocks is a problem in its own right thanks to the drug price debate, but the real drag on this healthcare ETF is the 22.69% weight to the healthcare providers industry, meaning this healthcare ETF features significant exposure to the Medicare For All debate. First Trust Health Care AlphaDEX Fund (FXH)Source: Shutterstock Expense ratio: 0.63%Alternatively-weighted, or smart beta, funds have caught on with advisors and investors in recent years, but when it comes to the sector funds in this group, there are often two-fold reminders. When things are going well for that sector, smart beta sector funds can outperform their cap-weighted rivals. When that sector falls out of favor, there is little or no downside protection in alternatively-weighted sector funds.Meet the First Trust Health Care AlphaDEX Fund (NYSEARCA:FXH), a healthcare ETF that has recently been taken to task in significant fashion. This healthcare ETF uses a mix of growth and value traits to build its portfolio, a methodology that can lead to upside when the sector is performing well, but in the current environment, FXH is being hit on multiple fronts.A combined weight of 39.60% to biotechnology and pharmaceuticals stocks exposes FXH to the drug price debate. Second, this healthcare ETF has devotes 17.48% of its weight to healthcare providers, meaning Medicare For All is dinging this fund's performance as well. Put all that together and FXH is experiencing epic April showers with a month-to-date loss of 8.57%.Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 High-Yielding Dividend Stocks That Won't Wilt * 4 Energy Stocks Soaring as Trump Tightens on Iran * 7 Tech Stocks With Too Much Risk, Not Enough Upside Compare Brokers The post 3 Healthcare ETFs to Sell Amid Political Headwinds appeared first on InvestorPlace.

  • Can The Stock Market Keep Rising After A Strong First Quarter?
    Investor's Business Daily

    Can The Stock Market Keep Rising After A Strong First Quarter?

    The stock market's rebound this year may leave investors wondering if there's any gas left in the tank. CLS Investments offers three 'resilient' ETF ideas.

  • ETF Trends

    4 ETFs to Consider with Big Pharma on the Senate’s Hot Seat

    Big pharmaceutical companies were on the hot seat at Capitol Hill today with CVS Health, Cigna, Prime Therapeutics, Humana, and UnitedHealthcare's OptumRx testifying before the Senate Finance Committee on the rising cost of prescription drugs. Among the topics discussed included rebates paid by drug makers contributing to the high costs and the drug industry's pursuit of profits--all to shift the blame from the pharmaceutical companies to the drug makers. U.S. President Donald Trump has already lambasted the pharmaceutical industry for the rising costs associated with prescription drugs.

  • Why These Pharma ETFs Rallied on Thursday

    Why These Pharma ETFs Rallied on Thursday

    A few pharma ETFs hit a one-month high on Feb 28. Why?

  • ETF Trends

    Pharmaceutical ETFs Break Out on Horizon Pharma’s Positive Drug Results

    Pharmaceutical sector-related ETFs stood out Thursday after Horizon Pharma (HZNP) revealed positive test results for its treatment of thyroid eye disease, or TED. Among the better performing non-leveraged ETFs of Thursday, the First Trust Nasdaq Pharmaceuticals ETF (FTXH) rose 1.8%, Invesco Dynamic Pharmaceuticals ETF (PJP) gained 1.5% and SPDR Pharmaceuticals ETF (XPH) increased 2.3%. Horizon Pharma shares surged 32.5% Thursday following the release of positive test results in its Phase 3 trial of its thyroid eye disease drug, teprotumumab, TheStreet reports.

  • A Look at Pharma ETFs Post Q4 Results

    A Look at Pharma ETFs Post Q4 Results

    The strong results but downbeat guidance led to decent returns in the pharma ETFs over the past month.